Vanda Pharmaceuticals (VNDA) Short-term Investments (2010 - 2026)

Vanda Pharmaceuticals has reported Short-term Investments for 17 years, with the latest figure at $148.3 million in Q1 2026.

• Quarterly Short-term Investments fell 35.28% year-over-year to $148.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $148.3 million (down 35.28% YoY) and the FY2025 annual result came in at $179.0 million, down 34.27% from the prior year.
• Short-term Investments declined to $148.3 million in Q1 2026 per VNDA's latest filing, from $179.0 million in the prior quarter.
• Over five years, Short-term Investments peaked at $405.4 million in Q3 2022 and troughed at $147.3 million in Q1 2023.
• A 5-year average of $274.1 million and a median of $272.3 million in 2024 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2023 and 2024: Short-term Investments slumped 59.99% in 2023, then soared 82.58% in 2024.
• Over 5 years, Short-term Investments stood at $331.8 million in 2022, then slipped by 23.92% to $252.4 million in 2023, then gained by 7.88% to $272.3 million in 2024, then sank by 34.27% to $179.0 million in 2025, then declined by 17.16% to $148.3 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $148.3 million, $179.0 million, and $223.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.